MK-677 Side Effects: Safety Signals and Warnings
MK-677 safety concerns are compound-specific. The main listed side effects are Increased appetite, Water retention and edema, and Muscle pain. The main warning signals are Not FDA approved - investigational compound, May impair glucose tolerance and increase insulin resistance with prolonged use, and May increase risk in patients with existing diabetes or prediabetes.
Direct Answer
Ibutamoren reliably raises GH and IGF-1 and now has a recruiting Phase 3 pediatric program, but that trial has not yet established benefit. Earlier studies showed modest body-composition effects alongside appetite, edema, glucose, and heart-failure concerns. Its strongest current case is as an investigational oral option for selected pediatric growth hormone deficiency, not general performance use.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Growth Hormone
- Evidence context
- Clinical research in pediatric growth hormone deficiency and oral GH-secretagogue pharmacology
Reported Side Effects
- Increased appetite
- Water retention and edema
- Muscle pain
- Joint pain
- Elevated fasting blood glucose
- Lethargy
- Numbness and tingling in extremities
Warnings
- Not FDA approved - investigational compound
- May impair glucose tolerance and increase insulin resistance with prolonged use
- May increase risk in patients with existing diabetes or prediabetes
- A prior hip-fracture study reported a congestive-heart-failure safety signal; fluid retention and cardiometabolic risk remain important
- Long-term safety data beyond 2 years is limited
- Contraindicated in patients with active malignancy (GH/IGF-1 axis stimulation)
Known or Plausible Interactions
- Insulin and oral hypoglycemics (MK-677 can impair glucose tolerance)
- Corticosteroids (may blunt GH response)
- Other GH secretagogues (additive effects on GH release)
Regulatory Context
Not FDA-approved. LUM-201 is investigational and is being studied in the recruiting Phase 3 OraGrowtH pediatric growth-hormone-deficiency trial (NCT06948214). Ibutamoren is prohibited by WADA in competitive sport under growth-hormone secretagogues.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Growth Hormone and IGF-1 Elevation (Level B), Lean Body Mass (Level B), Sleep Quality (Level B), and Appetite Increase (Level B) |
| Primary citation count | 4 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of MK-677?
MK-677 safety concerns are compound-specific. The main listed side effects are Increased appetite, Water retention and edema, and Muscle pain. The main warning signals are Not FDA approved - investigational compound, May impair glucose tolerance and increase insulin resistance with prolonged use, and May increase risk in patients with existing diabetes or prediabetes.
What is the evidence level for MK-677?
MK-677 is rated Level B. Its current research status is Phase 3.
What is MK-677 best known for?
Clinical research in pediatric growth hormone deficiency and oral GH-secretagogue pharmacology.
Where can I read the full MK-677 evidence review?
The full evidence review is available at https://examinepeptides.com/library/mk-677.
Related Guides
How to Cite This Page
ExaminePeptides. "MK-677 Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/mk-677-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.